Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase EARLY_PHASE1 1Phase 1/2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 2Other solid neoplasm 1

Conditions

Neoplasms 2Solid Tumor 1Neoplasm Metastasis 1

Interventions

Paclitaxel 291Gemcitabine 254Carboplatin 254Cisplatin 251Radiotherapy 219Cyclophosphamide 218Irinotecan 184pembrolizumab 181Docetaxel 174Bevacizumab 166Capecitabine 148Nivolumab 141Fluorouracil 132Dexamethasone 125Bortezomib 123Oxaliplatin 115Cytarabine 113Erlotinib Hydrochloride 112Temozolomide 110Sorafenib 110Doxorubicin 106Rituximab 105Leucovorin 105Etoposide 105Filgrastim 99Everolimus 97Lenalidomide 95Pemetrexed 90Ipilimumab 90fludarabine phosphate 84

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Completed × LY3022855 × Clear all
NCT02265536 2024-10-28

A Study of LY3022855 In Participants With Breast or Prostate Cancer

Eli Lilly and Company

Phase 1 Completed
34 enrolled 17 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT01346358 2024-09-19

A Study of IMC-CS4 in Subjects With Advanced Solid Tumors

Eli Lilly and Company

Phase 1 Completed
52 enrolled 23 charts
Tumor-Agnostic

Neoplasms

NCT02718911 2023-10-16

A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors

Eli Lilly and Company

Phase 1 Completed
72 enrolled 23 charts
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡